IP Library Granted Patent US 9,610,277
Granted Patent B2
US 9,610,277 · App. 14/899,912 · Granted Apr 4, 2017

Formula comprising a hypolipidemic agent

Inventors: Jitendre D. Patel (Ahmedabad, IN); Prakash Davadra (Ahmedabad, IN); Snehal Patel (Ahmedabad, IN); Shafiq Sheikh (Ahmedabad, IN)
Assignee: Cadila Healthcare Limited
A61K31/40A61K9/2009A61K9/2013
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,610,277
App. No.
14/899,912
Granted
Apr 4, 2017
Kind
B2
Abstract

The present invention relates to the stable pharmaceutical composition of a suitable hypolipidemic agent. Preferably, the present invention discloses novel formulations of the compound of formula (I), or pharmaceutically acceptable salts of compounds of formula (I). More particularly the present invention relates to the stable pharmaceutical composition of compounds of formula (I) comprising compounds of formula (I) or its pharmaceutically acceptable salts, wherein the pH of the formulation is maintained above 7.

Claims (31)

1. A stable pharmaceutical composition comprising a compound of formula (I):

wherein

R is alkylthio or thioalkyl;

M + represents a metal cation;

the pH of the composition is above 7; and

the composition comprises

i) suitable alkalinizers or suitable pH modifying agents which maintain the pH of the formulation above 7, and optionally

ii) a suitable stabilizer; and

iii) one or more other pharmaceutically acceptable excipients.

2. The pharmaceutical composition as claimed in claim 1 wherein R is selected from alkylthio or thioalkyl and M + represents Mg +2 .

3. The pharmaceutical composition as claimed in claim 1 wherein R is SCH 3 .

4. The pharmaceutical composition as claimed in claim 1 wherein the alkalinizers or pH modifying agents is selected from attapulgite, bentonite, calcium carbonate, calcium phosphate, calcium sulphate, mono ethanolamine, tri ethanolamine, potassium bicarbonate, potassium citrate, potassium hydroxide, sodium bicarbonate, Disodium hydrogen phosphate, mono basic potassium phosphate, Dicalcium phosphate, meglumine, light or heavy magnesium oxide.

5. The pharmaceutical composition as claimed in claim 4 wherein the alkalinizers or pH modifying agents is Disodium hydrogen phosphate or magnesium oxide.

6. The pharmaceutical composition as claimed in claim 1 wherein the stabilizers are selected from the classes of suitable antioxidants or chelating agents.

7. The pharmaceutical composition as claimed in claim 6 , wherein the antioxidants are selected from citric acid, alpha tocopherol, sodium sulphite, sodium metabisulphite, butylated hydroxy anisole (BHA), BHT (2,6-di-tert-butyl-4-methylphenol), monothioglycerol, Vitamin C (ascorbic acid), propyl gallate or suitable combinations thereof.

8. The pharmaceutical composition as claimed in claim 6 wherein the chelating agent is selected from Disodium EDTA, citric acid or its salts, maleic acid, chlorambutol, chlorhexidine or its salts, chlorocresol or their suitable combinations.

9. The pharmaceutical composition as claimed in claim 1 wherein the other pharmaceutical excipients are selected from suitable diluents, fillers, disintegrants, binder, lubricants, glidants, wetting agents and solvent(s).

10. The pharmaceutical composition as claimed in claim 9 wherein the binder is selected from acacia alginic acid, tragacanth, carboxymethylcellulose sodium, poly (vinylpyrrolidone), compressible sugar, ethyl cellulose, gelatin, liquid glucose, methyl cellulose, povidone and pregelatinized starch or suitable combinations thereof.

11. The pharmaceutical composition as claimed in claim 9 wherein the diluent or filler is selected from dibasic calcium phosphate, kaolin, sucrose, mannitol, microcrystalline cellulose, powdered cellulose, precipitated calcium carbonate, sorbitol, starch or suitable combinations thereof.

12. The pharmaceutical composition as claimed in claim 9 wherein the lubricant is selected from calcium stearate, magnesium stearate, mineral oil, stearic acid, zinc stearate or suitable combinations thereof.

13. The pharmaceutical composition as claimed in claim 9 wherein the disintegrant is selected from corn starch, potato starch, pregelatinized and modified starched thereof, sweeteners, clays, microcrystalline cellulose, carsium, alginates, sodium starch glycolate, gums selected from agar, guar, locust bean, karaya, pectin, tragacanth or combinations thereof.

14. The pharmaceutical composition as claimed in claim 9 wherein glidants is selected from colloidal silica, calcium silicate, magnesium silicate, silicon hydrogel, cornstarch, talc or suitable combinations thereof.

15. The pharmaceutical composition as claimed in claim 1 wherein the pharmaceutical composition is in the form of a tablet or a caplet or a capsule or a powder or a suspension in a liquid or an aerosol formulation or solutions.

16. The pharmaceutical composition as claimed in claim 1 prepared by direct compression, wet granulation or dry granulation.

17. The pharmaceutical composition as claimed in claim 16 wherein the composition is prepared by direct compression comprising mixing the drug with all the pharmaceutical excipients required and then either compressing into tablets or filled in capsules.

18. The pharmaceutical composition as claimed in claim 3 wherein M + represents Na + or K + .

19. The pharmaceutical composition as claimed in claim 3 wherein M + represents Ca +2 or Mg +2 .

20. The pharmaceutical composition as claimed in claim 1 wherein the compound of formula (I) is the compound of formula (Ia):

21. The pharmaceutical composition as claimed in claim 1 wherein the alkalinizer or pH modifying agent is selected from the group consisting of potassium bicarbonate, potassium citrate, sodium bicarbonate, disodium hydrogen phosphate, and monobasic potassium phosphate.

22. The pharmaceutical composition as claimed in claim 20 wherein the alkalinizer or pH modifying agent is selected from the group consisting of potassium bicarbonate, potassium citrate, sodium bicarbonate, disodium hydrogen phosphate, and monobasic potassium phosphate.

23. The pharmaceutical composition as claimed in claim 20 wherein the alkalinizer or pH modifying agent is disodium hydrogen phosphate or magnesium oxide.

Assignments (2)
CHANGE OF NAME Recorded Nov 28, 2023
From: CADILA HEALTHCARE LIMITED
To: ZYDUS LIFESCIENCES LIMITED
Reel/Frame 065679/0990 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 21, 2015
From: PATEL, JITENDRE D.; DAVADRA, PRAKASH; PATEL, SNEHAL; SHEIKH, SHAFIQ
To: CADILA HEALTHCARE LIMITED
Reel/Frame 037345/0511 →
Priority Claims (1)
IN 2470/MUM/2013 · Jul 25, 2013 · national
Continuity (1)
Related Publication 20160136131A1 · May 19, 2016